IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT06978361 pour Post-acne Atrophic Scars est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Comparison of Efficacy of Microneedling With Platelet Rich Plasma Vs Microneedling With Topical Insulin in the Treatment of Acne Scars
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT06978361 est un essai interventionnel pour Post-acne Atrophic Scars. Son statut actuel est : en recrutement. L'étude a débuté le 1 mars 2025 et vise à recruter 116 participants. Dirigé par Khyber Teaching Hospital, l'essai devrait être terminé d'ici le 31 décembre 2025. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 18 mai 2025.
Résumé succinct
This study compares the outcome of two procedures for the treatment of atrophic acne scars.
Description détaillée
Post acne scars develop due to severely inflamed and nodulocystic acne. Numerous methods exist for the treatment of post acne scars including lasers , microneedling and chemical peels etc . This study is to compare the efficacy two procedures.
Titre officiel
Comparison of Efficacy of Microneedling With Autologous Platelet-Rich Plasma vs Microneedling With Topical Insulin in the Treatment of Atrophic Acne Scars
Conditions
Post-acne Atrophic ScarsAutres identifiants de l'essai
- 938/DME/KMC
Numéro NCT
Date de début (réel)
2025-03-01
Dernière mise à jour publiée
2025-05-18
Date de fin (estimée)
2025-12-31
Inscription (estimée)
116
Type d'essai
Interventionnel
PHASE
N/A
Statut
En recrutement
Mots clés
Post-acne atrophic scars
Microneedling with autologous Platelet- Rich Plasma
Microneedling with topical insulin
Microneedling with autologous Platelet- Rich Plasma
Microneedling with topical insulin
Objectif principal
Traitement
Plan d'attribution
Randomisé
Modèle d'intervention
Parallèle
Masquage
Aucun (ouvert)
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalGroup A , Microneedling with autologous PRP Patients in group A will undergo microneedling with autologous PRP i.e cleansing of the treatment area with an antiseptic solution will be performed.Topical anesthetic will be applied to the area for 20-30 mins .Approximately 10ml of blood will be drawn into sterile tubes. blood sample will be placed in centrifuge 10-15mins which separates the blood components, allowing for the collection of PRP .Then sterile microneedling device will be used to begin the procedure by adjusting the needle depth according to scar severity.Controlled microinjuries to the skin will be made by moving the device in a systematic pattern over the treatment area .After microneedling ,immediately harvested PRP will be applied to the treated area ,allowing it to penetrate into the microinjuries .Patient will be asked for consideration of aftercare instructions ,including avoiding sun exposure , harsh skincare products and strenuous exercise for few days. | Microneedling with Autologous Platelet Rich Plasma Patients in group A will undergo Microneedling with autologous PRP |
ExpérimentalGroup B , Microneedling with Topical insulin Patients in group B will undergo microneedling with Topical insulin i.e cleansing of the treatment area with an antiseptic solution will be performed.Topical anesthetic will be applied to the area for 20-30 mins to reduce discomfort during the procedure.Then sterile microneedling device will be used to begin the procedure by adjusting the needle depth according to scar severity.Controlled microinjuries to the skin will be made by moving the device in a systematic pattern over the treatment area .After microneedling Insulin (Regular) will be applied immediately to the treated area. insulin will be allowed to penetrate into the microinjuries created by the microneedling for about 30 mins . Patient will be asked for consideration of aftercare instructions ,including avoiding sun exposure , harsh skincare products and strenuous exercise for few days. | Microneedling with Topical Insulin Patients in group B will undergo Microneedling with Topical insulin ( regular). |
Critère principal d'évaluation
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Efficacy of treatment | Efficacy will be determined by using the Goodman and Baron's Scarring Grading System as" Percentage of decrease in acne scar grade" i.e calculated through subtracting post treatment grade from pre treatment grade and then multiplying it with 100 in both treatment groups . | 6 months |
Critères d'éligibilité
Âges éligibles
Adulte
Âge minimum
18 Years
Sexes éligibles
Tous
Patients confirmed with post-acne atrophic scars . No prior treatment for scars in last 6 months.
-
- Patient with active acne or other skin conditions (e.g eczema , psoriasis). Patients on oral or topical retinoids. Pregnant or lactating Mothers. Patients with recurrent herpes simplex infection. Previous Hx of keloids / hypertrophic scarring. Deranged blood glucose levels. Bleeding disorders
Khyber Teaching HospitalPartie responsable de l'essai
Soaiba Naeem, Investigateur principal, Doctor, Khyber Teaching Hospital
Contact central de l'essai
Contact: Soaiba Naeem, MBBS, +923139493991, [email protected]
1 Centres de l'essai dans 1 pays
KPK ,Pakistan
Khyber Teaching Hospital, Peshawar, KPK ,Pakistan, 25000, Pakistan
En recrutement